1 There were no acute or late grade 5 toxic effects.
2 There were no adverse events either immediately or at 2-week
3 Acceptability of the intervention was high and
there were no adverse events.
4 There were no associations between induction, graft loss, and
5 However,
there were no associations between protein clusters and any m
6 There were no CAC differences between lifestyle and placebo i
7 44%), neovascular glaucoma was noted in 1 patient (2%), and
there were no cases of corneal opacity.
8 There were no clinical signs of bowel ischaemia during the fo
9 However,
there were no correlations between ascorbic acid and other bi
10 There were no correlations between drug concentrations and HI
11 There were no deaths in the ultralow-risk tamoxifen-treated a
12 In a modified intent-to-treat population,
there were no differences between latiglutenase and placebo g
13 At the post-test (26 wk),
there were no differences between the iCST and TAU groups in
14 There were no differences in allergic disease between LEAP gr
15 There were no differences in any specificity measures.
16 There were no differences in enamel and dentin densities betw
17 There were no differences in Model for End-Stage Liver Diseas
18 ly unaffected by development of intestinal inflammation and
there were no differences in previously published metabolic m
19 inear regression and adjusting for socioeconomic variables,
there were no differences in QOL or functional scores in the
20 d thrombocytopenia were prolonged in the intensive arm, but
there were no differences in serious nonhematological toxicit
21 There were no differences in the change from baseline in vess
22 During 2-year follow-up,
there were no differences of survival rates and occurrences o
23 After a median follow-up of 32 months,
there were no grade 3 toxicities.
24 There were no indications of acute toxicity up to 7 days afte
25 There were no indications of transgenerational acclimation to
26 There were no large imbalances between drug groups on baselin
27 There were no meaningful changes in body composition.On the b
28 There were no participants.
29 Safety was not explicitly addressed in any study, but
there were no reports of adverse events.
30 Conversely,
there were no safety concerns with very low LDL-cholesterol c
31 There were no serious adverse events or discontinuations due
32 Conversely, among those with higher CCL5 levels,
there were no significant associations between the microbiota
33 There were no significant between-group differences in the se
34 There were no significant differences among the NAFL, NASH, a
35 There were no significant differences among the treatment gro
36 with colonoscopy follow-up within 8 to 30 days (n = 27176),
there were no significant differences between follow-up at 2
37 There were no significant differences between groups in patie
38 Results
There were no significant differences between morning and aft
39 There were no significant differences between the 2 experimen
40 ed in ASD patients and family members compared to controls,
there were no significant differences in allele frequencies b
41 There were no significant differences in baseline demographic
42 There were no significant differences in CSF cytokine or chem
43 There were no significant differences in image contrast, sens
44 ized Medicare beneficiaries treated by a general internist,
there were no significant differences in overall 30-day morta
45 There were no significant differences in recurrent myocardial
46 There were no significant differences in the odds ratios for
47 There were no significant differences in transplant and pretr
48 There were no significant interactions of genotypes with calc
49 There were no statistically significant associations between
50 or patients presenting to the ED with acute extremity pain,
there were no statistically significant or clinically importa